Outputs (6)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study (2021)
Journal Article
Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., Wu, K. L., Bishton, M., Collins, G. P., Peyrade, F., Lee, Y., Neuenburg, J. K., & Tam, C. S. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 14, Article 179. https://doi.org/10.1186/s13045-021-01188-x

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer... Read More about Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Journal Article
Bishton, M. J., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., Manson, J., Nanduri, V., Earp, K., Flower, L., Amarnani, R., Rankin, J., Sen, E. S., Tattersall, R. S., Crooks, C. J., Aston, J., Siskova, V., West, J., & Bythell, M. (2021). A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. British Journal of Haematology, 194(6), 1039-1044. https://doi.org/10.1111/bjh.17768

We assessed the validity of coded healthcare data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013–2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., Shrubsole, C., Gray, N., Lewis, K., Tivey, A., Bishton, M. J., Hawkes, E., Ahearne, M. J., Osborne, W., Collins, G. P., Illidge, T., Linton, K. M., Cwynarski, K., Burton, C., & Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis (2021)
Journal Article
Rampotas, A., Wilson, M. R., Lomas, O., Denny, N., Leary, H., Ferguson, G., McKay, P., Ebsworth, T., Miller, J., Shah, N., Martinez‐Calle, N., Bishton, M., Everden, A., Tucker, D., El‐Hassad, E., Hennessy, B., Doherty, D., Prideaux, S., Faryal, R., Hayat, A., …Eyre, T. A. (2021). Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 194(2), 365-377. https://doi.org/10.1111/bjh.17513

Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line ‘attenuated’ or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenu... Read More about Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., Griffith, J., Fields, P., Gunawan, A., Oliver, R., Booth, S., Kothari, J., Fox, C. P., Martinez-Calle, N., McMillan, A., Bishton, M., Collins, G. P., & Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.